Terns Pharmaceuticals touts mid-stage success for NASH drug, stock falls
09 Aug 2023
Clinical ResultPhase 2
Terns Pharmaceuticals said a high dose of its experimental oral NASH treatment helped reduce liver fat in a Phase IIa trial.
The Foster City, CA-based biopharma said Tuesday in a release that TERN-501, a once-a-day THR-β agonistTHR-β agonist, met the primary endpoint and all secondary endpoints in the DUET trial.
The study tested three dose levels of TERN-501 — 1 mg, 3 mg and 6 mg — as a monotherapy, as well as in combination with TERN-101, an FXR agonistFXR agonist candidate. It assessed liver fat using a measuring system called magnetic resonance imaging, proton density fat fraction, or MRI-PDFF.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.